このエントリーをはてなブックマークに追加
ID 13960
Eprint ID
13960
フルテキストURL
Thumnail 106_187.pdf 649 KB
タイトル(別表記)
Studies on the effect of chemotherapy for multiple myeloma with analysis of bone lesion Part 1. Combination chemotherapy effect for multiple myeloma with aclarubicin, vincristine, cyclophoshamide and prednisolone including analysis on prognostic factors
著者
和泉 健 岡山大学医学部第二内科学教室
抄録
Sixty-one patients with multiple myeloma consisting of 45 previously untreated and 16 previously treated patinets were given combination therapy of aclarubicin, vincristine, cydlo-phosphmide and prednisolone. The overall response rate evaluated by 50% reduction in M-protein was 47%. The median survival time 40 months, which indicated satisfactory effectiveness. The previously untreated patients with stage Ⅲ disease had a much higher response rate (58%) than those with stage Ⅱ (33%). There was no significant difference in the 5-year survival between the patients with stage Ⅲ (33%) and stage Ⅱ (33%) disease. These findings indicate the effectiveness of the therapy for stage Ⅲ cases, especially patients with stage Ⅲ disease under good control showed long-term survival of more than 5 years. Marked symptomatic inpovement was observed in 77%. For patients with advanced bone lesion the therapy was also valuable. The multivariate anaysis (proportional hazard model of Cox) of individual biochemical and clinical variables showed that the tumor was the most significant variable related to prognos-tic factor followed by good and poor control and serum calcium level. Hematologic toxicity, infection, nausea and vomiting occurred frequently, although the incidence of ECG change (9%) was low and transient.
キーワード
multiple myeloma
combination chemotherapy
prognostic factor
multivariative analysis
bone status
備考
原著
発行日
1994
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
106巻
3-4号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
187
終了ページ
198
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/106/3-4/106_3-4_187/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/index.html
参考文献
1) Sezaki T : Aclarubicin in thr treatment of multiple myeloma. Jpn Clin Oncol (1984) 14, 353-358.
2) Greipp PR, Raymond NM, Kyle RA and O'Fallon WM : Multiple myeloma : Significance of plasmablastic subtype in morphological classification. Blood (1985) 65, 305-310.
3) Bartl R : Bone marrow histology in myeloma : its importance in diagnosis, prognosis, classification and staging. Br J Haematol (1982) 51, 361-375.
4) Kurihara K : Bone marrow changes following chemotherapy for multiple myeloma-A clinicopath-ological study of biopy cases. Acta Haematol Jpn (1987) 50, 876-889.
5) Yamazaki T : Combination chemotherapy for mulitiple myeloma with five cytotoxic drugs : Analysis on prognostic factors with special reference to cellular morphology. Dokkyo J Med Sci (1984) 11, 137-148.
6) Dure BMG and Salmon SE : A clinical staging system for multiple myeloma : Corelation of mea-sured myeloma cell mass with presenting clinical features, response to treatment, and surival. Cancer (1975) 36, 842-854.
7) Sezaki T : Tumor distribution classification system for multiple myeloma : Clinical features and prognosis. Acta Haematol Jpn (1986) 49, 1784-1791.
8) Brucher H : Myelomprobleme. D Tsch Med Wochenschr (1966) 37, 1629-1634.
9) Alexanian R : Chemotherapy for multiple myeloma. Cancer (1984) 53, 583-588.
10) Alexnian R : Treatment of multiple myeloma. JAMA (1969) 208, 1680-1685.
11) Mcintyre OR : Current concept in cancer multiple myeloma. N Engl J Med (1979) 301, 193-196.
12) Alexnian R : Treatment of multiple myeloma. Acta Haematol (1980) 63, 237-240.
13) Alexanian R : Ten-year survival in multiple myeloma. Arch Intern Med (1985) 145, 2073.
14) Hori S : Antitumor activity of new anthracyline antibioties. Gann (1977) 68, 658-690.
15) Bennet JM and Silber R : Phase Ⅱ sutdy of adriamycin and Bleomycin in patients with multiple myeloma. Cancer Treat Rep (1978) 62, 1367-1369.
16) 足立富郎 : 骨髄腫の生存期間からみたM蛋白および血清アルブミンによる効果判定. 日血会誌 (1987) 50, 272.
17) 梅田政法 : 多発性骨髄腫に対するVCAP療法. 臨床血液 (1987) 4, 1227-1237.
18) Case DC : Improved survival time in multiple myeloma treated with melphalan, prednisolone, cyclophoshamide, vincristine and BCNU. Am J Med (1977) 63, 897-903.
19) Brian GM : Improved survival duration with combination chemotherapy inductoion for multiple myeloma. A Southwest Oncology Group Study. J Clin Oncol (1986) 4, 1227-1237.
20) Kyle AR : Long term survival in multiple myeloma. N Engl J Mad (1983) 308, 842-854.
21) Alexanian R : Prognostic factor in multiple myeloma. Cancer (1975) 36, 1192-1201.
22) 武元良整 : 多発性骨髄腫の予後推定-多変量解析による検討ー. 臨床血液 (1985) 26, 1580-1585.
23) 渡邊栄二 : 多発性骨髄腫の予後因子ー重回帰型生命法による分析ー. 日血会誌 (1987) 50, 53-58.
24) 足立富郎 : 多発性骨髄腫における化学療法に関する臨床研究(第4法)ー長期生存に関する予後因子についてー. 臨床血液 (1988) 29, 494-501.
25) Simosson B : Bicohemical markers in multiple myeloma : a multivariate analysis. Br J Haematol (1985) 20, 345-351.
26) Alexanin R and Durie BMG : Beta 2 microglobulin in multiple myeloma. Am J Hematol (1985)20 345-351.
27) Kyle RA : Multiple myeloma-review of 869 cases-. Mayo Clin Proc (1975) 50, 29-40.
28) Bataille R : Prognostic factors and staging in multiple myeloma. J Clin Oncol (1986) 4, 80-87.
29) Mcintyre OR : Correlation of abnormal immunoglobulin with clinical features of myeloma. Arch Intern Med (1975) 135, 46-52.
30) 瀬崎達雄 : 多発性骨髄腫における化学療法に関する臨床的検討 : 第1報 Melophalan, Ifosfamide, Pred-nisolone 交替併用療法の治療効果について. 臨床血液 (1982) 23, 847-853.
31) Alberts DS and Salmon SE : Adriamycin (NSC-123127) in the treatment of alkylator resistant multiple myeloma. A pilot study. Cancer Treat Rep (1975) 59, 345.
32) Alberts DS, Durie BGM and Salmon SE : Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse. Lancet (1976) 1, 926-928.
33) Bataille R : Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982). Anticancer Res (1984) 4, 339-346.
言語
Japanese
OAI-PMH Set
岡山大学
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Sort Key
1
Eprints Journal Name
joma